Skip to content
Menu

Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $135

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price target from $187 to $135.

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price target from $187 to $135.

Read at benzinga.com